13th Meet The Professor
Advanced International Breast Cancer Course (AIBCC)

Padua, September 21-23, 2017

The Conference will include:

1) Lectures:
Internationally recognized speakers provide a balanced overview of selected topics

2) Clinical Case Discussions:
Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced breast cancer will be presented. All participants will be requested to select their vote among a predefined list of options. Expert panelists will then provide their opinion and discuss the audience’s choices.

3) Highlights:
Internationally recognized speakers give an update of significant advances presented at major meetings (ASCO, ESMO, SABCS, ST. GALLEN) on preselected topics
[Preliminary Program]

Thursday, September 21st

8.00  Registration

9.15  Introduction to the Conference
      Pierfranco Conte, Gabriel N. Hortobagyi

**SESSION I - LIFE STYLE AND BREAST CANCER**
Chairmen: Gabriel N. Hortobagyi, Stefania Migliuolo

9.30  Body Mass Index: role as risk factor and predictor of endocrine therapy efficacy
      Andrea De Censi

10.00 Hormone replacement therapy: the good and the bad
      Marco Gambacciani

10.30 Breast cancer and pregnancy
      Fedro Peccatori

11.00 Q&A

11.15  *Coffee break*

**SESSION II - HIGH RISK WOMEN AND PERSONALISED SCREENING**
Chairmen: Andrea De Censi

11.45 Identification of high risk women: from family history to multigene panels
      Marco Montagna

12.15 Personalized screening (including women with dense breasts or breast implants/augmentation)
      Enrica Baldan

12.45 Q&A

13.00  *Lunch*

14.00 **Multidisciplinary Tumor Board 1 – Management of women at high risk of breast cancer**
Chairmen: Gabriel H. Hortobagyi, Luigi Pescarini
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.
Participants: Enrica Baldan, Andrea De Censi, Marco Gambacciani, Sibylle Loibl, Stefania Migliuolo, Marco Montagna, Stefania Montemezzi, Enrico Orvieto, Fedro Peccatori, Massimo Rugge

**SESSION III - SURGERY & RADIOTHERAPY**
Chairmen: Jacek Jassem, Elefterios Mamounas

15.00 Management of in situ carcinoma: state of art
tbd

15.30 Sentinel node biopsy: when should be spared?
Oreste Gentilini

15.50 Sentinel node biopsy: before or after NACT?
Elefterios Mamounas

16.10 Lipofilling: are preclinical data fully reassuring?
Francesco Bertolini

16.30 Lipofilling after breast cancer: the surgeon's point of view
tbd

16.50 Radiation therapy: when more is better and when less is good
Philip Poortmans

17.20 Q&A

17.30 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2017

18.00 Lecture of the Awardee

18.30 Cocktail

20.00 Adjourn

Friday, September 22nd

SESSION IV – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY
Chairmen: Aleix Prat, Massimo Rugge

9.00 Baseline assessment: new AJCC classification
Gabriel N. Hortobagyi

9.30 HER2 testing guidelines for the clinicians: equivocal means yes or no?
Giuseppe Viale

10.00 Genomic tests: clinical utility after TailoRx and Mindact
Maria Vittoria Dieli

10.30 Liquid biopsy (ctDNA, CTC, miRNA): ready for clinical use?
Leticia de Mattos-Arruda

11.00 Q&A

11.15 Coffee Break

SESSION V – ACTIONABLE PATHWAYS IN BREAST CANCER SUBTYPES
**Chairmen:** Pierfranco Conte, Sibylle Loibl

11.45 Luminal tumors and endocrine resistance
Stephen Johnston

12.15 Targeting the immune system: TN and beyond
Peter Schmid

12.45 HER2+ and trastuzumab resistance
Aleix Prat

13.15 Q&A

13.30 Lunch

14.30 **Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy)**
Chairmen: Fernando Bozza, Pierfranco Conte
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.
Participants: Hesham A. Gaballah Elghazaly, Gabriel N. Hortobagyi, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Elefterios Mamounas, Miguel Martin, Stefania Migliuolo, Fedro Peccatori, Philip Poortmans, Aleix Prat, Massimo Rugge, Giuseppe Viale

16.00 **Coffee break**

**SESSION VI – ADJUVANT TREATMENTS**
Chairmen: Gabriel N. Hortobagyi, Stephen Johnston

16.20 HR+ disease: when more is better – Michael Gnant
: when less is good – Giuseppe Curigliano

17.00 HER2+ disease: when more is better - Javier Cortes Castan
: when less is good – Pier Franco Conte

17.40 Triple Negative: when more is better- Valentina Guarneri
: when less is good – Miguel Martin

18.20 Q&A

18.30 Adjourn
Saturday, September 23rd

SESSION VIII – ABC PATIENTS
Chairmen: Hesham A. Gaballah Elghazaly, Valentina Guarneri

9.00 New therapeutic algorithms

HR+ ABC - Stephen Johnston
HER2+ ABC - Sibylle Loibl
TN ABC – Hope Rugo

10.30 Q&A

10.45 Highlights from major meeting (ASCO, ESMO, SABCS, ST GALLEN)
Jassem Jacek

11.15 Coffee break

11.45 Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Chairmen: Pierfranco Conte, Miguel Martin
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

13.15 Adjourn and final evaluation questionnaire

[Aims]

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogenetists besides the “classic” clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 13th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 13th AIBCC will award the 7th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.
[Addressed to]
Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

[Directors]

Pierfranco Conte
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Gabriel N. Hortobagyi
Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer Center
Houston (USA)

[Scientific Committee]

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl
German Breast Group
Department of Medicine and Research
University of Frankfurt (D)

Miguel Martin
Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (S)
Stefania Migliuolo
Europa Donna Italia
Milan (I)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Philip Poortmans
President of ESTRO; President-Elect of ECCO
Department of Radiation Oncology
Institut Curie
Paris (F)

Aleix Prat
Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)

[Speakers]

Enrica Baldan
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Francesco Bertolini
Department of Emato-Oncology
European Institute of Oncology
University of Milan (I)

Fernando Bozza
Division of Breast Surgery
Istituto Oncologico Veneto IRCCS
Padua (I)

Javier Cortes Castan
Institute of Oncology
Vall d’Hebron (VHIO)
Barcellona (S)

Giuseppe Curigliano
Department of Oncology
European Institute of Oncology
University of Milan (I)

Andrea De Censi
Medica and Preventive Oncology
E.O. Galliera Hospital
Genua (I)
Leticia De Mattos-Arruda
Institute of Oncology
Vall d’Hebron (VHIO)
Barcellona (S)

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Marco Gambacciani
Obstetrics & Gynecology Unit
S. Chiara Hospital
Pisa (I)

Oreste Gentilini
Breast Unit
S. Raffaele Hospital
Milan (I)

Michael Gnant
Department of Surgery
Medical University
Wien (A)

Eleuterios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center
Orlando (USA)

Marco Montagna
Hereditary Tumors Group Breast and Ovary Cancer
Department of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto
University of Padua (I)

Stefania Montemezzi
Department of Radiology
University Hospital
Verona (I)

Enrico Orvieto
General Pathology and Cytopathology Unit
Department of Medicine-DIMED
University of Padua (I)

Luigi Pescarini
Department of Radiology
Diagnostic Breast Unit
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Massimo Rugge
General Pathology & Cytopathology Unit
Department of Medicine-DIMED
Section of Oncology

University of Padua (I)

Hope Rugo
Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Peter Schmid
Centre for Experimental Cancer Medicine
Bart Cancer Institute
Queen Mary University
London (UK)

Giuseppe Viale
Department of Pathology
European Institute of Oncology
University of Milan (I)

[ Meeting Venue ]

Palazzo del Bo
Via VIII Febbraio, 2
Padua (I)